Financial conflicts of interest are common in the drug industry. Photo: Wodicka/ullstein bild via Getty Images

An analysis by the publication Science has "found widespread after-the-fact payments or research support" from pharmaceutical companies to expert officials who advised the Food and Drug Administration to approve those companies' drugs.

Why it matters: Conflicts of interest are common in the health care industry, especially between companies that make drugs and doctors who prescribe them. But this new analysis indicates people who sit on official government panels, and who are supposed to evaluate drugs impartially, are getting rewarded later from the drug companies they helped.

Go deeper

Updated 25 mins ago - Politics & Policy

Coronavirus dashboard

Illustration: Aïda Amer/Axios

  1. Politics: Ex-FDA chief: Pence campaigning after COVID exposure puts others at risk — Mark Meadows: "We are not going to control the pandemic" — COVID-19 looms over White House Halloween celebrations.
  2. Health: Fauci says maybe we should mandate masks if people don't wear them — America was sick well before it ever got COVID-19U.S. reports over 80,000 new cases for 2nd straight day.
  3. World: Spain declares new state of emergency — Polish President Andrzej Duda tests positive for COVID-19.

Senate advances Amy Coney Barrett nomination, setting up final confirmation vote

Photo: Xinhua/Ting Shen via Getty Images

The Senate voted 51-48 on Sunday to advance the Supreme Court nomination of Judge Amy Coney Barrett, setting up a final confirmation vote for Monday.

Why it matters: It's now virtually inevitable that the Senate will vote to confirm President Trump's third Supreme Court nominee before the election, which is just nine days away.

Felix Salmon, author of Capital
3 hours ago - Economy & Business

Wall Street is living up to its bad reputation

Illustration: Sarah Grillo/Axios

Recent headlines will have you convinced that Wall Street is hell-bent on living up to all of its stereotypes.

Driving the news: Goldman Sachs is the biggest and the boldest, paying more than $5 billion in fines in the wake of the 1MDB scandal, in which billions were stolen from the people of Malaysia.